Clinical Trial Update: Pediatric Arthritis Study of Certolizumab Pegol [Phase 3]

View source ↗

Summary

Results from a Phase 3 pediatric trial of certolizumab pegol for polyarticular-course juvenile idiopathic arthritis have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB BIOSCIENCES GmbH | Conditions: Polyarticular-course Juvenile Idiopathic Arthritis (JIA) | Phase 3 | Status: COMPLETED | Results posted: 2024-10-23